
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 6, 2015**

CRYOLIFE, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or Other Jurisdiction
of Incorporation)

1-13165
(Commission File Number)

59-2417093
(IRS Employer
Identification No.)

1655 Roberts Boulevard, N.W., Kennesaw, Georgia 30144

(Address of principal executive office) (zip code)

Registrant's telephone number, including area code: (770) 419-3355

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Section 5 Corporate Governance and Management

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 6, 2015, CryoLife, Inc. (“CryoLife” or the “Company”) and Bruce G. Anderson, the Company’s Vice President, U.S. Sales and Global Marketing, entered into a Separation and Release Agreement (the “Agreement”) that is expected to become effective eight days after its execution (the “Effective Date”). The Company had previously disclosed that Mr. Anderson was leaving the Company to pursue other opportunities in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 9, 2015, which is incorporated herein by reference.

The Agreement provides for the termination of Mr. Anderson’s employment, effective September 8, 2015 (the “Termination Date”). In accordance with the terms of the Agreement, Mr. Anderson will receive the following:

- A total amount of \$281,200 distributed in a lump sum on January 29, 2016;
- An additional lump sum in the amount of \$23,687 representing the value of twelve (12) months of continued coverage under CryoLife’s group medical plan (“COBRA Continuation Coverage”), such amount to be paid on the first pay day following the Effective Date;
- Reimbursement of costs, in an aggregate amount not to exceed \$15,000, for up to twelve months of outplacement services through an outplacement provider mutually agreed upon by Mr. Anderson and the Company; and
- The benefits that accrue to an employee upon retirement pursuant to the Company’s stock plans, including, without limitation, that his options granted pursuant to applicable option agreements shall remain exercisable, to the extent vested as of the Termination Date, until the earlier of the end of the applicable option term or thirty-six months from the Termination Date, and otherwise in accordance with the applicable option agreement.

In return for the benefits described above, Mr. Anderson agreed to release and forever discharge CryoLife and certain related parties, including present and former officers and directors of the Company, from any and all claims and causes of action that Mr. Anderson had or may have in the future that are based on acts or facts arising or occurring prior to the Effective Date. Mr. Anderson also agreed that he would (i) protect certain confidential information, proprietary information and trade secrets of CryoLife and, (ii) for a period of 24 months after the Effective Date, (A) not solicit any customers or active prospects of CryoLife, on behalf of a competing business with whom he has had material contact, (B) not solicit or induce any employees of CryoLife to terminate their employment with CryoLife, and (C) not directly or indirectly perform work or services that are the same or substantially similar to those he performed for CryoLife. For a twelve month period after the Effective Date, Mr. Anderson,

upon reasonable request by the Company, agreed to provide the Company with information and assistance up to four hours per week.

Mr. Anderson has the right to revoke the Agreement at any time on or before October 14, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, CryoLife, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CRYOLIFE, INC.

Date: October 9, 2015

By: /s/ D. Ashley Lee
Name: D. Ashley Lee
Title: Executive Vice President, Chief
Operating Officer and Chief
Financial Officer